117 results
8-K
EX-10.1
ADIL
Adial Pharmaceuticals Inc
26 Apr 24
Departure of Directors or Certain Officers
4:01pm
, including the costs of mediation, arbitration, litigation, court fees, and reasonable attorneys’ fees incurred in connection with such an action.
19
424B3
ADIL
Adial Pharmaceuticals Inc
23 Apr 24
Prospectus supplement
4:00pm
of the Private Securities Litigation Reform Act of 1995. All statements other than statements of current or historical fact contained in this prospectus … of derivative litigation against directors and officers, even though an action, if successful, might provide a benefit to us and our stockholders. Our
424B5
ADIL
Adial Pharmaceuticals Inc
18 Apr 24
Prospectus supplement for primary offering
5:31pm
, litigation matters and our ability to obtain patent protection for our or our licensee’s technologies;
significant lawsuits, including patent or stockholder … litigation;
general political and economic conditions; and
other events or factors, many of which are beyond our control, including those resulting
8-K
EX-1.1
ADIL
Adial Pharmaceuticals Inc
18 Apr 24
Entry into a Material Definitive Agreement
5:27pm
or deemed made that has not been publicly disclosed at least one (1) Trading Day prior to the date that this representation is made.
(p) Litigation. Except
424B5
n67e0r5ji23dbo gf
25 Jan 24
Prospectus supplement for primary offering
4:30pm
424B3
t9fs22b2thy42hwre3
20 Nov 23
Prospectus supplement
7:46am
8-K
EX-10.1
iahdoffi7ur8vbn
24 Oct 23
Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
4:48pm
8-K
EX-99.1
3halsx8 mjj
26 Sep 23
Other Events
9:08pm
8-K
EX-2.3
8x6z i43h380p12
21 Sep 23
Entry into a Material Definitive Agreement
4:10pm
8-K
7dq9t8eev8rx3uz7
11 Sep 23
Regulation FD Disclosure
6:03am
424B3
o921n42e
28 Jul 23
Prospectus supplement
6:13pm